Qualigen Therapeutics, Inc.
QLGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9,632 | $5,742 | $5,300 | $19,070 |
| - Cash | $38,777 | $332 | $30 | $1,175 |
| + Debt | $3,237 | $3,617 | $844 | $0 |
| Enterprise Value | -$25,909 | $9,027 | $6,113 | $17,895 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,582 | -$1,579 | -$2,573 | -$750 |
| % Margin | – | – | – | – |
| Net Income | -$2,038 | -$1,685 | -$2,646 | -$856 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.73 | -1 | -1.82 | -0.19 |
| % Growth | -73% | 45.1% | -857.9% | – |
| Operating Cash Flow | -$2,141 | -$1,098 | -$1,589 | -$2,270 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2,141 | -$1,098 | -$1,589 | -$2,270 |